| Pharmaceutical Information |
| Drug Name |
Dutasteride |
| Drug ID |
BADD_D00736 |
| Description |
Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner.[A1909] Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to enhance the therapeutic response. Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled trials in androgenetic alopecia.[A178333,A178336] |
| Indications and Usage |
Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].[L10568] |
| Marketing Status |
approved; investigational |
| ATC Code |
G04CB02 |
| DrugBank ID |
DB01126
|
| KEGG ID |
D03820
|
| MeSH ID |
D000068538
|
| PubChem ID |
6918296
|
| TTD Drug ID |
D0A9YA
|
| NDC Product Code |
11014-0027; 64918-1904; 63629-1222; 63629-1223; 65162-750; 71205-039; 71205-278; 11014-0247; 64566-0013; 25000-011; 10695-152; 11014-0340; 59057-004; 73309-169; 53345-037; 72865-140; 14501-0006; 65862-797; 31722-131; 11014-0215; 64918-1032; 51013-190; 64380-763; 70771-1347; 10888-8101; 11014-0428; 51508-006; 10888-8108; 38779-3086; 53104-7612; 59057-005; 64918-1031; 71052-601; 42806-549; 69784-712; 51552-1551; 51927-5120; 61187-002; 64566-0015; 59651-021; 63629-8207; 70518-2378; 63379-016; 68554-0079; 51407-157; 68071-2610; 72578-019; 11014-0216; 11014-0392; 55111-076; 62991-3182 |
| UNII |
O0J6XJN02I
|
| Synonyms |
Dutasteride | 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one | Avodart | GG 745 | 745, GG | GG-745 | GG745 | GI198745 |
|
| Chemical Information |
| Molecular Formula |
C27H30F6N2O2 |
| CAS Registry Number |
164656-23-9 |
| SMILES |
CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
